Zealand Pharma announces closing of collaboration and license agreement with Roche
Company announcement – No. 12 / 2025
Zealand Pharma announces closing of collaboration and license agreement with Roche
Copenhagen, Denmark, May 9, 2025 – Zealand Pharma A/S ("the Company" or 'Zealand Pharma') (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces that all closing conditions in the collaboration and license agreement with Roche announced on March 12, 2025 have been satisfied, including regulatory conditions, and the agreement has become effective.
'We are incredibly excited to launch this partnership, which represents a step change to realize Zealand Pharma's vision of becoming a key player in the future management of obesity. Roche ticked all the right boxes for what we were looking for in a partner and we look very much forward to working closely together to unlock the full potential of petrelintide to benefit people who are overweight or obese', said Adam Steensberg, Chief Executive Officer at Zealand Pharma.
# # #
About Zealand Pharma A/SZealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand's business and activities, please visit www.zealandpharma.com.
ContactsAdam Lange (Investors)Vice President, Investor Relations Zealand PharmaEmail: alange@zealandpharma.com
Neshat Ahmadi (Investors)Investor Relations ManagerZealand PharmaEmail: neahmadi@zealandpharma.com
Anna Krassowska, PhD (Investors and Media) Vice President, Investor Relations & Corporate Communications Zealand Pharma Email: akrassowska@zealandpharma.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
13 minutes ago
- Wall Street Journal
EU Confirms Further One-Year Delay to Bank Trading Desk Rules
The European Union confirmed the delay by one more year of tougher global rules for banks' trading businesses. The bloc is seeking to level the playing field for European lenders amid U.S. President Trump's deregulation push. The region is home to BNP Paribas and Deutsche Bank, whose investment-bank trading desks could stand at a disadvantage if they have to comply with the rules ahead of their competitors across the Atlantic.
Bloomberg
18 minutes ago
- Bloomberg
Europe's Nuclear Ambitions Face €241 Billion Funding Challenge
The European Union's ambition to scale up nuclear energy as part of its 2050 climate neutrality goal will cost €241 billion ($280 billion), posing funding challenges, according to a draft document. More than four-fifths of investment under that base-case scenario would go on building new reactors, taking the bloc's capacity to 109 gigawatts by 2050, according to a draft of the European Commission's Nuclear Illustrative Program seen by Bloomberg News.
Bloomberg
18 minutes ago
- Bloomberg
Italy Seeks More Time to Reach NATO's New Defense Spending Goal
Italy will need a decade to meet NATO's planned defense spending target of 5% of GDP, Foreign Minister Antonio Tajani said on Thursday, as the alliance debates how quickly it can achieve the steepest military ramp-up since the Cold War. The leaders of the North Atlantic Treaty Organization are expected to commit to allocating at least 3.5% of economic output to core defense requirements by 2032, plus an additional 1.5% to protect infrastructure at the the summit in The Hague on June 24-25.
